Artwork

المحتوى المقدم من TGen Talks. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة TGen Talks أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !

Episode 63: Unlocking the Secrets of T Cell Therapy Resistance

23:03
 
مشاركة
 

Manage episode 375689946 series 1936276
المحتوى المقدم من TGen Talks. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة TGen Talks أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
For a patient diagnosed with multiple myeloma, a type of blood cancer, there are more treatment options than ever and traditional chemotherapies that cause debilitating side effects have been all but completely replaced by immunotherapies, treatments that help a patient's own immune system better fight the disease. But in many patients, a chosen immunotherapy drug can show great promise in early treatments, yet seemingly stop working altogether as time goes by. In a paper that was published in Nature Medicine, TGen's Dr. Jonathan Keats explains how upwards of 65% of relapsing multiple myeloma patients could be affected by mutations that impact targeted T cell treatments. On this episode, you'll hear about a study that found how these cancer cells were mutating to evade the very drugs prescribed to fight them. The findings could help clinicians and patients choose from among a variety of T cell therapies for multiple myeloma to find treatments that best match a patient’s available tumor targets. Dr. Keats also discusses his broader work in multiple myeloma and plans for a rapid sequencing center that will place valuable genomic-informed data in the hands of treating physicians in just 48 hours. All this and more on TGen Talks.
  continue reading

83 حلقات

Artwork
iconمشاركة
 
Manage episode 375689946 series 1936276
المحتوى المقدم من TGen Talks. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة TGen Talks أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
For a patient diagnosed with multiple myeloma, a type of blood cancer, there are more treatment options than ever and traditional chemotherapies that cause debilitating side effects have been all but completely replaced by immunotherapies, treatments that help a patient's own immune system better fight the disease. But in many patients, a chosen immunotherapy drug can show great promise in early treatments, yet seemingly stop working altogether as time goes by. In a paper that was published in Nature Medicine, TGen's Dr. Jonathan Keats explains how upwards of 65% of relapsing multiple myeloma patients could be affected by mutations that impact targeted T cell treatments. On this episode, you'll hear about a study that found how these cancer cells were mutating to evade the very drugs prescribed to fight them. The findings could help clinicians and patients choose from among a variety of T cell therapies for multiple myeloma to find treatments that best match a patient’s available tumor targets. Dr. Keats also discusses his broader work in multiple myeloma and plans for a rapid sequencing center that will place valuable genomic-informed data in the hands of treating physicians in just 48 hours. All this and more on TGen Talks.
  continue reading

83 حلقات

كل الحلقات

×
 
Loading …

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.

 

دليل مرجعي سريع

استمع إلى هذا العرض أثناء الاستكشاف
تشغيل